Abstract:BackgroundColorectal cancer (CRC) is one of the most common malignancies and its incidence and mortality are increasing yearly. 5-Fluorouracil (5-FU) has long been used as a standard first-line treatment for CRC patients. Although 5-FU-based chemotherapy is effective for advanced CRC, the consequent resistance remains a key problem and causes the poor prognosis of CRC patients. Thus, there is an urgent need to identify new biomarkers to predict the response to 5-FU-based chemotherapy.MethodsCRC samples were retrieved from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). The immune-related genes were retrieved from the ImmPort database. Single-cell sequencing results from colorectal cancer were obtained by the ArrayExpress database. 5-FU resistance-related genes were filtered and validated by R packages. ESTIMATE algorithms were used to assess the tumor microenvironment (TME). KEGG and GO analysis were performed to explore the biological signaling pathway for resistant-response patients and sensitive-response patients in the tumor microenvironment. pRRophetic algorithms were used to predict 5-FU sensitivity. GSEA and GSVA analysis was performed to excavate the biological signaling pathway of the RBP7 gene.ResultsNine immune-related genes were identified to be associated with 5-FU resistance and poor disease-free survival (DFS) of CRC patients and the signature of these genes was developed in a DFS-prognostic model. Four immune-related genes were determined to be associated with 5-FU resistance and overall survival (OS) of CRC patients. The signature of these genes was developed an OS-prognostic model. ESTIMATE scores showed a significant difference between 5-FU resistant and 5-FU sensitive CRC patients. Resistant-response patients and sensitive-response patients to 5-FU based chemotherapy showed different GO and KEGG enrichment on the tumor microenvironment. RBP7, as a tumor immune microenvironment (TIME) related gene, was found to have the potential of predicting chemotherapy resistance and poor prognosis of CRC patients. GSEA analysis showed multiple signaling differences between the high and low expression of RBP7 in CRC patients. Hypoxia and TNFα signaling via NFκB gene sets were significantly different between chemotherapy resistant (RBP7High) and chemotherapy sensitive (RBP7Low) patients. Single-cell RNA-seq suggested RBP7 was centrally distributed in endothelial stalk cells, endothelial tip cells, and myeloid cells.ConclusionsImmune-related genes will hopefully be potential prognostic biomarkers to predict chemotherapy resistance for CRC. RBP7 may function as a tumor microenvironment regulator to induce 5-FU resistance, thereby affecting the prognosis of CRC patients.

[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues]

[Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer]

Correlation between chemosensitivity and clinilcopathological features in 83 cases of colorectal cancer

The Correlation Between in Vitro Chemosensitvity Test and Expression of Multidrug Resistant 1 and Multidrug Resistance-Associated Proteins in Gastric Cancer

Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer

Chemotherapy sensitivity and associated gene expression in human breast cancer cells

Profiling Protein Markers Associated with the Sensitivity to Concurrent Chemoradiotherapy in Human Cervical Carcinoma.

Correlation between p53 mutations and chemosensitivity in colorectal carcinoma cells

Expression of Drug Resistance-associated Tumor Genes in Human Colonic Carcinoma Tissue and its Clinical Significance

The Relationship Between Mismatch Repair (MMR) Proteins Status and the Response to Conventional Neoadjuvant Therapy in Colorectal Cancer (CRC).

Correlation Between Chemosensitivity To Anticancer Drugs And Bcl-2 Expression In Gastric Cancer

The Chemotherapy Sensitivity and Gene Expression in Lung Cancer Cell Lines

Sensitivity of different human colorectal tumor cell lines to commonly used chemotherapeutic drugs in vitro

Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer

Combination of Histoculture Drug Response Assay and Qpcr As an Effective Method to Screen Biomarkers for Personalized Chemotherapy in Esophageal Cancer.

Significance Of Multidrug Resistance Gene-Related Proteins In The Postoperative Chemotherapy Of Gastric Cancer

Anticancer chemosensitivity and growth rate of freshly separated human colorectal cancer cells assessed by in vitro DNA synthesis inhibition assay

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

[Preliminary Study on Relationship Between Multi-Drug Resistance-Associated Protein 4 and Radiosensitivity of Rectal Cancer].

Expressions and Clinical Significance of HIF-1α and Multidrug Resistance Genes in Human Colorectal Adenocarcinoma

Study on the Correlation Between the Expression of MRP2 and MRP3 and Efficacy of Chemotherapy in Hepatocellular Carcinoma Patients with Tumor Thrombi in Major Portal Vein